-
Cytek Biosciences, Inc. (CTKB) Reports In-Line Q2 EPS ; Offers Guidance
-
Piper Sandler: 'Opportunities to Buy Dislocated Stocks after Prints'
-
TD Cowen Downgrades Cytek Biosciences Inc (CTKB) to Hold
-
Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance
-
Cytek® Biosciences (CTKB) announces Cytek Muse Micro system
-
Cytek Biosciences, Inc. (CTKB) reported revenue at $57.5 million
-
Goldman Sachs Downgrades Cytek Biosciences Inc (CTKB) to Sell
-
Cytek® Biosciences (CTKB) Reports Prelim FY24 Results
-
Cytek® Biosciences (CTKB) Announces $50M Share Buyback
-
Cytek Biosciences Inc (CTKB) PT Lowered to $8.25 at Piper Sandler
-
Cytek Biosciences, Inc. (CTKB) Reports In-Line Q3 EPS ; Offers Guidance
-
Cytek® Biosciences (CTKB) Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
-
Cytek Biosciences, Inc. (CTKB) Misses Q2 EPS by 8c ; Offers Guidance

